Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients

NCT06334120 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06334120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06334120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
Lead sponsor
Bayer
Phase
Observational
Overall status
Recruiting
Start date
September 25, 2024
Completion date
June 30, 2028
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer